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Summary Stable angina is a form of coronary artery disease. Its potential to progress requires
the most appropriate treatment in order to reduce the incapacitating effect of an acute angina
attack and to avoid long-term cardiovascular events. With or without revascularization, pharma-
cological treatment is an essential component of this treatment strategy, which also involves
lifestyle and diet. Statins and aspirin have been shown to be effective in preventing differ-
ent aspects of coronary artery disease overall. The efﬁcacy of other classes of treatment has
been demonstrated in contexts such as stable angina (including postmyocardial infarction) and
heart failure (under speciﬁc conditions of dosing) for beta-blockers and in contexts such as
heart failure, postinfarction and following revascularization for angiotensin-converting enzyme
inhibitors. Along with the oldest classes of treatment, such as nitrates (and related derivatives),
beta-blockers and calcium channel blockers, new classes of treatments with entirely (trimetazi-
dine, ivabradine) or partly (nicorandil) different mechanisms of action have now been added.
The latest antianginal to obtain marketing authorization, ranolazine, is not yet available in
France. The different levels of evidence of the efﬁcacy of these pharmacological products
vary greatly and overall are higher for those developed most recently. None is devoid of side
effects, which must be taken into account in these patients, many of whom are elderly and
polymedicated.
. All rights reserved.© 2011 Elsevier Masson SASAbbreviations: ACE, angiotensin-converting enzyme; BPM, beats per minute; cGMP, cyclic guanosine monophosphate; LDL,
ow-density lipoprotein.
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Résumé L’angor stable est une forme d’insufﬁsance coronaire dont le potentiel évolutif
justiﬁe la mise en œuvre des mesures thérapeutiques les plus adaptés pour limiter l’effet
invalidant des crises angineuses et éviter la survenue d’événements cardiovasculaires à long
terme. Avec ou sans revascularisation, le traitement pharmacologique reste une composante
essentielle de cette approche thérapeutique qui comporte aussi l’application de règles hygiéno-
diététiques. L’efﬁcacité préventive des statines et de l’aspirine est démontrée pour les
différentes manifestations de la maladie coronaire prises dans leur globalité. Celle d’autres
classes thérapeutiques l’a été dans des contextes qui peuvent être associés à un angor stable
comme les suites d’un infarctus du myocarde et l’insufﬁsance cardiaque (dans des conditions
précises d’administration) pour les bêtabloquants ou comme le post-infarctus, l’insufﬁsance
cardiaque et après revascularisation pour les inhibiteurs de l’enzyme de conversion. Pour la
prévention des crises d’angor, à côtés des classes thérapeutiques les plus anciennes comme
les dérivés nitrés (et apparentés), les bêtabloquants et les antagonistes calciques sont venu
s’ajouter des classes thérapeutiques ayant des mécanismes d’action différents, totalement
(trimétazidine, ivabradine) ou partiellement (nicorandil). Le dernier antiangineux à avoir
obtenu une autorisation de mise sur le marché, la ranolazine, n’est pas encore disponible en
France. Les niveaux de preuve de l’efﬁcacité de ces médicaments sont très variables et glo-
balement plus élevés pour les plus récents. Aucun n’est dénué d’effets indésirables et ceux-ci
doivent être pris en compte chez ces patients souvent âgés et polymédicamentés.
© 2011 Elsevier Masson SAS. Tous droits réservés.
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Coronary artery disease is the leading cause of death in
France, ahead of the different forms of cancer [1]. One of
its clinical manifestations is stable angina, which is deﬁned
as a clinical syndrome typically characterized by discomfort
in the chest elicited by exertion or emotional stress that
is relieved by rest or nitroglycerine and can be attributed
to myocardial ischaemia [2]. Unlike the different acute
coronary syndromes, stable angina is not immediately life-
threatening [2]. However, progression to a more severe form
of the disease is impossible to exclude. This risk alone
merits a robust treatment strategy consistent with cur-
rent scientiﬁc knowledge [2,3]. Two recent French surveys
have shown that a signiﬁcant proportion of coronary artery
disease patients deemed to be stable still develop angina
attacks [4,5]. The European [2] and American [3] recom-
mendations are relatively old (2006 and 2007, respectively)
and do not (or only to a very limited extent) take account
of recent strategic and pharmacological developments. This
is probably one of the reasons why several reviews on the
management of stable angina have recently been published
[6—11].
Medical treatment is the cornerstone of
stable angina
Beyond the context of refractory symptoms in medically
treated patients, the place of revascularization compared
with medical treatment has been debated for a long time.
In its recommendations on stable angina (2006), the Euro-
pean Society of Cardiology emphasized that the treatment
of patients with stable angina has two goals [2]. First, to
improve prognosis by preventing myocardial infarction and
death. Second, to minimize or abolish symptoms. On the
other hand, the most recent European Recommendations
o
t
m
mn Myocardial Revascularization (2010) stressed that revas-
ularization has a favourable effect on prognosis only in
atients with patent myocardial ischaemia, even when they
ave no symptoms [12]. Regardless, medical treatment
emains the basis of management in all situations, includ-
ng when revascularization has already been performed [13].
his supposes that the likelihood of severe coronary artery
isease has been properly assessed, because this assessment
nﬂuences the choice of the different diagnostic and treat-
ent strategies [6].
Several studies (COURAGE [14], AVERT [15], MASS II [16],
ARI 2D [17], etc.) have questioned the respective roles of
nd indications for revascularization and medical treatment
particularly when medical treatment achieves its objec-
ives in terms of controlling risk factors (COURAGE [14]) —
ut the door still remains open [7,11,18].
In France, percutaneous revascularization still has a
ajor place, even as a ﬁrst-line treatment. We do not intend
o enter this debate, which is far from being closed. Rather,
n this update on the medical treatment of stable angina,
e intend to deal with the different medical options, with
special focus on pharmacological agents that either are
lready commercialized in France or are currently applying
or it. We will also emphasize the optimization of medical
trategies, including patient-tailored medications. However,
etting a global strategy is a difﬁcult task because the dif-
erent data available are not necessarily comparable for the
ifferent options.
edical treatments for stable angina
edical treatment forms part of all of the management
ptions, including revascularization strategies. In addition
o antianginal medications, it includes essential rules for the
anagement of the patient’s overall cardiovascular risk. The
edical management of chronic stable angina according to
538 J.-L. Gayet et al.
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tigure 1. Medical management of chronic stable angina accordin
CE: angiotensin-converting enzyme; CVD: cardiovascular disease;
006 European Society of Cardiology Guidelines is presented
n Fig. 1.
isease-modifying treatments that inﬂuence
rognosis
n stable angina, the clear context of secondary prevention
hould lead to the systematic use of drugs proven to be
ffective in improving the prognosis of patients with coro-
ary artery disease, in terms of morbidity and mortality.
ost secondary prevention studies have recruited patients
ith various forms of established coronary disease, which
id not involve stable angina as a single clinical presenta-
ion (follow-up of acute coronary syndrome, asymptomatic
oronary artery disease, etc.). However, the context is suf-
ciently similar and occasionally confused (stable angina,
roportions unstated) to justify extrapolating the same
econdary prevention rules to all coronary artery disease
atients. The basis of non-speciﬁc treatment still remains
he adoption of an appropriate lifestyle (stopping all forms
f smoking, physical exercise, balanced diet, inﬂuenza vac-
ination, etc.).
T
m
a
othe 2006 European Society of Cardiology guidelines.
yocardial infarction; od: once daily; pcn: pectin casein nitrate.
Pharmacological treatment is based on four well-assessed
lasses of drugs: aspirin, statins, angiotensin-converting
nzyme inhibitors and beta-blockers.
spirin
recent review of the 2002 Antiplatelet Trialists’ Col-
aboration meta-analysis conﬁrmed in 2010 that aspirin
igniﬁcantly reduces the risk of thrombotic events in
atients with coronary artery disease [19]. However, the
ime for which aspirin is effective over the 24-hour cycle,
t the doses usually recommended for stable angina (75
o 100mg/day) or at even higher doses, varies greatly
etween patients [20]. Whether or not residual angina is
resent, aspirin always remains the basis of antithrombotic
reatment after an acute coronary syndrome or coronary
ngioplasty. Clopidogrel can be offered as an alternative
o aspirin when aspirin is not tolerated or contraindicated.
he association of aspirin and clopidogrel can be recom-
ended independently of the presence or absence of stable
ngina, particularly following acute myocardial infarction
r coronary angioplasty. Recent studies have highlighted
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the prevalence and sometimes the increased risk associated
with some form of resistance to these agents [21].
Statins
The effectiveness of statins in reducing the risk of car-
diovascular events in secondary prevention has been well
proven, with, in most cases, a low-density lipoprotein (LDL)-
cholesterol treatment goal of 1.00 g/L. The current question
concerns the effectiveness and tolerability of more intensive
treatments aimed at reaching lower goals. A meta-analysis
comparing more or less stringent goals shows increased ben-
eﬁt with more intensive treatments, without tolerability
problems [22]. However, these studies were generally con-
ducted on patients with more severe forms of coronary
artery disease and it is difﬁcult to extrapolate these results
to isolated stable angina. The results of the DUAAL study,
which showed atorvastatin and amlodipine to have similar
antianginal effects, should be conﬁrmed and would, were
it needed, be an additional reason for the systematic pres-
cription of a statin in patients with stable angina [23].
Angiotensin-converting enzyme inhibitors
The ﬁndings of the HOPE study support the prescription of an
angiotensin-converting enzyme (ACE) inhibitor for preven-
tion of cardiovascular complications in all high-risk patients,
which therefore includes those with stable angina [24].
The results of the EUROPA study further support this indi-
cation following myocardial revascularization [25]. These
situations are, of course, complementary to the classical
indications that may also be present in patients with stable
angina, notably following myocardial infarction and in left
ventricular dysfunction or heart failure.
Beta-blockers
Beta-blockers have been proven to provide beneﬁt in reduc-
ing long-term morbidity and mortality after myocardial
infarction [26]. They are therefore formally indicated in
this situation in patients with stable angina. On the other
hand, in the absence of a past history of myocardial infarc-
tion, their systematic use is not mandatory in isolated stable
angina. In addition, they are potent anti-ischaemic agents.
Antianginal drugs
For a long time, the evaluation of antianginal drugs was
only based on exercise-testing criteria, sometime associ-
ated with an evaluation of the frequency of ambulatory
heart attacks, which is slightly more clinically relevant [27].
Speciﬁc morbidity-mortality data on antianginal drugs in
patients with stable angina are only available for one cal-
cium channel blocker (nifedipine; ACTION trial [28]) and the
potassium channel activator, nicorandil (IONA trial [29]).
Beta-blockers
Beta-blockers remain the pivotal treatment for angina pec-
toris. They have long been used to treat stable angina,
which usually occurs in the context of increased adrener-
gic drive associated, for example, with effort or stress.
They selectively block the beta-adrenergic receptors and
thus prevent binding of the G-protein and activation of
t
b
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denyl cyclase. They have a dual haemodynamic effect with
egative inotropism and prolongation of diastole because
f the bradycardia they induce. By decreasing blood pres-
ure, they also reduce wall stress. Altogether, these effects
educe myocardial oxygen requirements and improve coro-
ary artery perfusion.
In patients with coronary artery disease, the doses usu-
lly recommended are those that keep the heart rate
ess or equal to 60 beats per minute (bpm) or even
ower in severe angina. The exercise test can be used
o adjust the exercise heart rate on treatment below
he pain threshold. No study has shown any one beta-
locker to be more effective than another in this indication
8].
Tolerability is a limiting factor in the use of beta-
lockers, at least at optimal doses. Severe bradycardia,
onduction abnormalities, severe peripheral arterial dis-
ase, asthma and severe obstructive bronchopulmonary
isease are all contraindications limiting their use. Addi-
ional factors limiting their use are the decreased physical,
sychological and sexual function that they may cause. Some
f these obstacles can be partly avoided by the use of
ardioselective beta-blockers. Heart failure has become an
ndication for the use of some of these drugs, although under
peciﬁc dosing conditions.
As noted above, beta-blockers have been proven to be of
eneﬁt for improvement of the prognosis after myocardial
nfarction, particularly following early administration, but
ot in stable angina [30].
alcium channel blockers
alcium channel blockers reduce calcium inﬂux into the
ell, producing dual vasodilating and negative inotropic
ffects, which respectively vary depending on the differ-
nt compounds. Dihydropyridines (amlodipine, felodipine,
sradipine, nicardipine and nifedipine) mostly have a periph-
ral vasodilating action and increase heart rate. Their
rolonged release pharmaceutical forms cause less tachy-
ardia and could therefore be preferred. They must be
ssociated with a beta-blocker or, failing this, with an
lternative cardiac slowing agent (e.g., ivabradine). The
on-dihydropyridines (diltiazem and verapamil) both have
peripheral vasodilating action and probradycardic and
yocardial depressant effects. Because of this, they are
n alternative to beta-blockers but are contraindicated
n left ventricular dysfunction or poorly controlled heart
ailure. They have been proven to be effective in exer-
ise tests and 24-hour Holter monitoring but they have
o inﬂuence on prognosis. In the ACTION trial, after a
.9-year mean follow-up, no effect of nifedipine com-
ared with placebo was demonstrated on a composite
ndpoint (death, acute myocardial infarction, refractory
ngina, new overt heart failure, debilitating stroke or
eripheral revascularization) or on mortality and acute
yocardial infarction, which were secondary endpoints
28].
Calcium channel blockers have not always been objec-
ively shown to improve stress angina when associated with
eta-blockers. They remain the reference treatment for
pastic angina.
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itrates
itrates are historically the leading therapeutic class used
o treat angina pectoris. There have been many studies on
heir mechanism of action [31]. They are indirect nitric
xide donors, which block calcium entry in smooth mus-
le cells and promote their relaxation through production of
yclic guanosine monophosphate (cGMP). Their main haemo-
ynamic effect is to reduce preload by venodilatation,
lthough at high doses they have an arterial vasodilating
ffect, causing dilatation of the epicardial arteries. They
romote redistribution of coronary blood ﬂow from healthy
o ischaemic areas [32]. Their antiaggregant effect, which
s, however, very limited, is explained by their action on
latelet cGMP.
The duration of action of nitrates has been increased
hrough the development of many pharmaceutical forms
sprays, patches, prolonged release tablets containing dif-
erent metabolites, etc.). However, the risk of tolerance
nd the possibility of a rebound effect, for which many
echanisms have been suggested [8], prevents the desired
ffect from being obtained over the whole 24-hour cycle
31,33,34]. Because of this, a therapeutic window must be
bserved with the different long-acting forms, particularly
y removing patches at night. Sublingual tablets remain the
eference treatment for acute attacks. Failure to respond to
ublingual treatment of an attack is an important indicator
f accelerated progression of angina, which every patient
ust be able to recognize.
Nitrates are usually well tolerated, although they may
ause headaches, restricting their use. Because of their
asodilating action, they increase heart rate and it is recom-
ended to combine them with preventative treatments such
s beta-blockers or calcium channel blockers, which have a
eart rate-lowering effect. Association with treatments for
rectile dysfunction is contraindicated as, by inhibiting type
phosphodiesterase, these prevent the degradation of cGMP
nd potentiate the effect of the nitrates [35].
olsidomine
he mechanism of action of molsidomine is very similar to
hat of nitrates, to which it is often linked. Because of its
iotransformation, molsidomine acts through the release of
ndothelial nitric oxide. Together with nitrates, it also has a
ery slight antiaggregant action, although, unlike nitrates, it
s not indicated for use in the treatment of acute angina but
nly as a disease-modifying treatment to prevent attacks.
Molsidomine has common adverse effects with the
itrates, particularly headaches, which may be worsened
hen it is used in association with other vasodilators. In
articular, as for nitrates, its association with type 5 phos-
hodiesterase inhibitors is contraindicated because of the
isk of severe hypotensive episodes.
icorandil
icorandil has a dual mechanism of action [36,37]. Part of
ts chemical structure gives it the same effect as nitrates.
he other part of the compound makes it similar to the
icotinamide-group vitamins, with the property of activat-
ng adenosine triphosphate-sensitive potassium channels.
his causes hyperpolarization, which inhibits calcium inﬂux
nto muscle cells and promotes relaxation (indirect calcium
[
o
r
[J.-L. Gayet et al.
hannel blocking effect). Because of this dual mechanism
f action, nicorandil does not suffer the treatment escape
henomenon seen with nitrates alone. Because it activates
otassium channels, nicorandil has a beneﬁcial effect on
schaemic preconditioning and has been shown to have a
ardioprotective effect in animal studies [37].
The antianginal activity of nicorandil has been demon-
trated in many studies [29,37]. Its prognostic beneﬁt was
hown against placebo in coronary artery disease patients
n the IONA study [29]. In this study, a signiﬁcant beneﬁt
as found for several composite indicators, including the
rimary endpoint (deaths from coronary artery disease, non-
atal myocardial infarction or unplanned hospitalization for
oronary artery disease: hazard ratio 0.83; 95% conﬁdence
nterval 0.72—0.97; P = 0.014). This result was mainly sup-
orted by a reduction in acute coronary events. Curiously,
n this study, nicorandil had no beneﬁt on symptoms assessed
y the Canadian classiﬁcation.
The main side effect of nicorandil is headache when
reatment is started, which may be avoided by increas-
ng doses gradually up to the optimal level. Ulcerations
ere initially described as buccal and rare at the begin-
ing of its clinical development [37]. However, several case
eports describing many other locations were subsequently
escribed (anal, colonic, vulvovaginal and penile), which
ay be severe although always reversible with treatment
essation.
rimetazidine
rimetazidine has a complex antianginal mechanism of
ction [38]. It acts mostly as a metabolic modulator,
hich optimizes myocardial energy expenditure on effort
y promoting myocardial glucose use to the detriment of
hat of fats (partial inhibition of fatty acid -oxidation
y reducing the mitochondrial activity of an enzyme, 3-
etoacyl coenzyme A thiolase) [38]. It increases coronary
eserve, although its antianginal effect is not due to
educed heart rate, myocardial depression or vasodilata-
ion.
A meta-analysis by the Cochrane Collaboration grouped
ogether comparative trials of trimetazidine versus placebo
r other antianginal agents in patients with stable angina
39]. The analysis showed that compared with placebo,
rimetazidine signiﬁcantly reduces the number of weekly
ttacks, nitrate use and the time to onset of signiﬁcant
T-segment depression. The authors, however, concluded
hat there was too little information to propose the use
f trimetazidine either as monotherapy or in association
n angina pectoris, although fewer people seemed to give
p treatment because of side effects than with the other
ntianginals. There are, indeed, only a few such studies,
ach of which included only a small number of patients.
recent report by the French National Pharmacovigilance
ommission (19 May 2009) found that trimetazidine could
nduce or increase Parkinsonian symptoms and asked for a
eassessment of the whole beneﬁt-risk balance of this drug
40]. Further to a procedure of re-evaluation, a decision
f suspension (but not withdrawal) of the French Autho-
ization of trimetazidine was pronounced (7 April, 2011)
41].
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Ivabradine
Ivabradine acts purely by decreasing heart rate through a
blockade of sinoatrial node If entry currents. It was ﬁrst
shown to be effective as an antianginal against placebo
(superiority) in coronary artery disease patients with sta-
ble angina [42], and then against atenolol (non-inferiority)
in the INITIATIVE study [43]. These studies ﬁrst led to it
being proposed as an alternative to beta-blockers when
beta-blockers cannot be used, particularly because of con-
traindications or intolerance. Ivabradine was also shown
to be complementary to atenolol in stable coronary artery
disease patients, based on ergometric criteria, in the ASSO-
CIATE study [44].
In the BEAUTIFUL morbidity-mortality study conducted
in patients with coronary artery disease and left ventric-
ular dysfunction, ivabradine did not affect the primary
composite outcome (cardiovascular death or admission for
new-onset or worsening heart failure). However, it was
shown to have a positive effect in patients who had a pre-
treatment heart rate greater or equal to 70 bpm, but only
on two secondary endpoints (fewer hospitalizations for fatal
or non-fatal myocardial infarction and fewer revasculariza-
tions) [45]. In this trial, 87% of patients had already received
a beta-blocker as background therapy. Both ASSOCIATE and
BEAUTIFUL results demonstrate that ivabradine should be
also indicated when angina is not sufﬁciently controlled with
a heart rate greater or equal to 70 bpm in patients optimally
treated with beta-blockers.
The most common adverse effect is the induction of
phosphenes, which resolve spontaneously when the treat-
ment is stopped and are responsible for discontinuation in
less than 1% of patients [46]. Phosphenes are caused by
hyperpolarization-activated cyclic nucleotide-gated recep-
tor inhibition in the retina [47]. Excessive bradycardia has
been reported, with an incidence of 2% at the recommended
dose of 7.5mg twice daily [46].
Ranolazine
Ranolazine is a selective inhibitor of late sodium cur-
rent, which prevents the intracellular calcium overload
that has been implicated as a negative factor in myocar-
dial ischaemia [48—50]. Ranolazine reduces myocardial wall
rigidity and improves myocardial perfusion without changing
either heart rate or blood pressure.
Ranolazine has been shown to have antianginal efﬁcacy
in three studies in coronary artery disease patients with
stable angina (MARISA, CARISA and ERICA) and is therefore
indicated for use in association with conventional antiangi-
nal therapy in patients who remain symptomatic [27,51,52].
Compared with placebo, ranolazine reduced worsening of
angina pectoris and improved exercise tolerance during
stress testing in a large study in patients with a history
of angina pectoris after acute coronary syndrome (MERLIN)
[53]. It has been used since 2006 in the USA and in most Euro-
pean countries, with a favourable decision by the French
Commission of Transparency [54].
The main side effects of ranolazine are dizziness, nausea
and constipation [49]. Prolongation of the QT interval may
occur, although this has never been deemed to be respon-
sible for torsades de pointes, particularly in patients who
experience dizziness [49]. Ranolazine also appears to reduce
o
o
p
t541
aemoglobin A1c in diabetic patients but the mechanism
nd implications of this ﬁnding remain to be established.
few precautions for use are required as it is metabolized
y cytochrome P450.
edical treatment strategies in stable
ngina
he choice of disease-modifying treatments that inﬂuence
rognosis raises a few problems. The COURAGE study clearly
emonstrated that all of these treatments should be used at
he maximum tolerated doses, closest to those that have
een proven to be effective in improving prognosis [14].
he questions already raised are those of the LDL choles-
erol goal and whether or not an ACE inhibitor should be
dministered routinely.
In the absence of contraindications, beta-blockers
emain the reference treatment to prevent angina attacks,
articularly after myocardial infarction. The role of other
ntianginals as an alternative or in addition depends on
ndividual patient features, cardiovascular risk factors and
oncomitant diseases. Poor lifestyle (including smoking,
edentary or dietary errors), which is common in this sit-
ation, also contributes to diseases other than angina and
ncreases the numbers of drugs that are being taken. The
ecent emergence of new antianginals offers additional
ptions to take these different factors into account.
The maximum tolerated dose of beta-blocker (or a highly
elective beta-blocker) should be used in patients with a
igh heart rate. Whenever this is impossible, adding ivabra-
ine should be considered. Ivabradine has also become
he treatment of choice in cases of beta-blocker intol-
rance (asthma, atrioventricular block, non-cardiovascular
ide effects). Probradycardic calcium channel blockers can
lso be used as an alternative.
The most common coexisting cardiovascular risk factor
s hypertension and, therefore, dihydropyridines or other
alcium channel blockers (diltiazem or verapamil) have a
ole in combined treatment with or as a substitute for beta-
lockers.
Conversely, if achieving optimal doses of these treat-
ents either alone or in association is limited by an
xcessively low heart rate or blood pressure, ranolazine
ecomes valuable because of the non-haemodynamic-effect
roﬁle.
Nitrates and related compounds such as molsidomine or
icorandil can be used in association with the treatments
escribed above. Apart from their common risks of adverse
ffects, particularly concomitant use of erectile dysfunc-
ion drugs, prescribers must be aware of the speciﬁc risk of
lceration with nicorandil.
Nitrates and ivabradine (when heart rate is greater or
qual to 70 bpm) have a role in association with beta-
lockers in patients with left ventricular dysfunction but
on-dihydropyridine calcium channel blockers are not rec-
mmended in this context. Patent heart failure has its
wn management regimens, which may include drugs with
roven antianginal effects, such as beta-blockers (under
heir own conditions of use in this indication), nitrates or
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vabradine. Calcium channel blockers no longer have a role
n this situation.
Better knowledge of the antianginals currently available
s needed, as many studies in the past have shown that
table angina is often inadequately treated and that man-
gement does not follow current recommendations [55,56].
ore recently, based on European ﬁndings, the investigators
rom the EuroHeart Survey in stable angina demonstrated a
irect relationship between inadequate treatment of sta-
le angina (antiaggregants, statins and beta-blockers) and
eath or myocardial infarction [57]. Finally, despite an indis-
utable improvement, more than half of patients admitted
or angioplasty in a United Kingdom study still had an inad-
quately controlled heart rate (≥ 60 bpm) or blood pressure
ver values recommended by the European Society of Cardi-
logy/European Society of Hypertension for at-risk patients
systolic blood pressure≥ 130mmHg) [58].
Patients with stable angina are becoming increasingly
lder and, in parallel, have an increasing number of coexist-
ng diseases [57]. These diseases expose patients to the risks
f side effects when combinations of drugs (antianginals or
thers) are needed. The ﬁndings of the EuroHeart Survey
howed that 42% and 16% of stable coronary artery patients
ere taking two and three antianginals, respectively [57].
his is important if we consider that antianginals such as
eta-blockers, calcium channel blockers and nitrates are not
lways devoid of side effects, especially of haemodynamic
ature.
The important harmful effect of increased heart rate
as been emphasized [59]. However, several clinical prac-
ice studies have also shown that a large number of patients
reated for stable angina have heart rates or blood pressures
hat are far too low and are liable to limit the necessary
djustments to treatment. The risk of excessively low blood
ressure in hypertensive coronary artery disease patients,
articularly the elderly, has recently been reviewed [60,61]
nd the availability of new antianginals that do not have
otentially harmful haemodynamic effects is therefore use-
ul.
onclusion
he increasing number of antianginal treatments may not
ave the desired effect if both the older and the new agents
re not correctly chosen and administered at the optimal
ecommended doses. The latest recommendations of the
uropean Society for Cardiology date from 2006 [2] and
he American College of Cardiology/American Heart Asso-
iation recommendations date from 2007 [3]. In France,
he French National Health Authority (Haute Autorité de
anté) proposed a guide for the management of coronary
rtery disease in 2007. This relates more to the long-
erm management strategy and makes limited reference
o the pharmacological treatment of stable angina (but
ore to preventative disease-modifying treatment) [62].
t would therefore be useful to have the recommenda-
ions updated, taking account of recent ﬁndings about
he effectiveness of non-interventional measures on prog-
osis and new treatments that have emerged in recent
ears.
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